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Abstract
Synthetic nucleic acids are commonly used laboratory tools for modulating gene expression and have the potential
to be widely used in the clinic. Progress towards nucleic acid drugs, however, has been slow and many challenges
remain to be overcome before their full impact on patient care can be understood. Antisense oligonucleotides
(ASOs) and small interfering RNAs (siRNAs) are the two most widely used strategies for silencing gene expression.
We first describe these two approaches and contrast their relative strengths and weaknesses for laboratory
applications. We then review the choices faced during development of clinical candidates and the current state of
clinical trials. Attitudes towards clinical development of nucleic acid silencing strategies have repeatedly swung
from optimism to depression during the past 20 years. Our goal is to provide the information needed to design
robust studies with oligonucleotides, making use of the strengths of each oligonucleotide technology.
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Overview
The ability to use synthetic agents to control gene
expression facilitates many aspects of biological re-
search and would have a transformative impact on the
treatment of many diseases. Oligonucleotides are one
promising class of synthetic agents. Such compounds
can be designed to recognize any species of cellular
DNA or RNA and, in theory, have the potential to
modulate gene expression and affect the course of
almost any disease.
This concept is not new. In 1978, Zamecnik first
reported that a synthetic oligonucleotide (at that time,
a rare and difficult to obtain type of compound)
complementary to Rous sarcoma virus 35S RNA acted
as an efficient inhibitor of protein expression [1–3]. In
spite of the obvious promise of this approach, progress
has been slow because of the need to overcome
many technical hurdles. Now, fuelled by advances
in antisense technology and the emergence of RNA
interference, the modulation of gene expression by
nucleic acids has become a routine tool for laboratory
research. For patient care, the field has seen repeated
disappointments that often mask the underlying steady
progress being made.
The concept is simple: a target RNA is chosen based
on a hypothesis about its physiological significance;
a complementary oligonucleotide is synthesized; gene
expression is assayed; and phenotypes are examined.
Reality is more complex. Here we describe strategies
for using nucleic acids to control gene expression,
with a focus on translating the technology into the
clinic.
Basic principles of oligonucleotide-mediated gene
silencing
Single-stranded antisense oligonucleotides (ASOs) and
RNA interference (RNAi) share their fundamental prin-
ciple: an oligonucleotide binds a target RNA through
Watson–Crick base pairing. An ASO must survive and
function as a single strand (Figure 1A). In contrast,
during RNAi, a small RNA duplex associates with the
RNA-induced silencing complex (RISC), one strand
(the passenger strand) is lost, and the remaining strand
(the guide strand) cooperates with RISC to bind com-
plementary RNA. In contrast to ASOs, the guide strand
is always associated with a complementary strand or a
protein (Figure 1B). This difference between the two
approaches leads to different strengths and weaknesses
that affect drug development.
Optimization strategies for antisense
oligonucleotides: chemical modification
Unmodified single-stranded DNA or RNA oligonu-
cleotides are too unstable to use in cells. The first
type of optimization to be developed was therefore the
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Figure 1. Comparison of the ASO and siRNA mechanisms. (A) ASOs must be stable as single-stranded oligonucleotides and find their
target alone. (B) siRNAs are delivered as duplexes and then taken up by Argonaute (AGO), part of the RNA-induced silencing complex.
Thus, the ‘antisense oligonucleotide’ that guides AGO to complementary mRNA is always present in the cell as a duplex or as part of a
protein complex. Note that RISC also engages in complex biology with endogenous small RNAs [71].
use of chemical modifications to increase the nuclease
resistance. The earliest major breakthrough was the
introduction of phosphorothioate (PS) linkages in place
of the phosphodiester bond [4] (Figure 2A). This mod-
ification greatly improved stability towards digestion
by nucleases. PS linkages also improved binding to
serum proteins in vivo, increasing half-life and per-
mitting greater delivery of active compound to tissues
[5,6]. ASOs that only contain PS modifications were
capable of producing antisense effects inside cells,
but potencies were not always high nor were reliable
results routine [7].
Another obstacle was inadequate affinity for in-
tended target sequences leading to low potencies.
Poor potencies force the use of high concentrations
of oligonucleotides, which can lead to ‘off-target’
effects—unintended phenotypes that are unrelated to
inhibition of the intended target gene. Off-target effects
can be due to recognition of other genes by binding
to sequences that are similar to the intended target.
Oligonucleotides can also bind directly to proteins and
affect their function. While direct binding to proteins
is generally considered an unwanted off-target effect in
the gene silencing field, it has spawned a field of its
own (see, for example, ref 8).
Chemical modifications can improve potency and
selectivity by increasing the binding affinity of oligonu-
cleotides for their complementary sequences. Widely
used modifications include 2′-O-methyl (2′-O-Me) [9],
2′-fluoro (2′-F) [10–13], and 2′-O-methoxyethyl (2′
MOE) [14,15] RNA (Figure 2B). Even more affinity
can be gained using oligonucleotides modified with
locked nucleic acid (LNA), which contains a methy-
lene bridge between the 2′ and 4′ position of the ribose
[16,17]. This bridge ‘locks’ the ribose ring in a confor-
mation that is ideal for binding, leading to high affinity
for complementary sequences [18]. Related bridged
nucleic acid (BNA) compounds have been developed
and share these favourable properties [19–27]. Their
high affinity has permitted the development of far
shorter oligonucleotides than previously thought pos-
sible which nonetheless retain high potency [28].
The chemistry for introducing 2′-O-Me, 2′-MOE, 2′
F, or LNA into oligonucleotides is compatible with
DNA or RNA synthesis, allowing chimeras with DNA
or RNA bases to be easily obtained. This compat-
ibility allows the properties of chemically modified
oligonucleotides to be fine-tuned for specific applica-
tions—a major advantage for development that makes
LNAs and other BNAs convenient tools for many
applications.
Amplifying the effectiveness of ASOs: RNase H
The RNA strand of DNA/RNA hybrids is cleaved by
the enzyme RNase H, an enzyme that exists in both
the nucleus and the cytoplasm of eukaryotic cells [29].
This catalytic cleavage can be exploited by synthetic
oligonucleotides to increase potency [30,31]. ‘Gap-
mer’ oligonucleotides contain two to five chemically
modified nucleotides (eg LNA or 2′-MOE) on each
terminus flanking a central eight to ten base ‘gap’
of DNA [13,32]. The chemically modified oligonu-
cleotides increase nuclease resistance and affinity for
target sequences, while the DNA gap permits the for-
mation of a DNA/RNA hybrid that can be a good
substrate for RNase H. Most of the ASOs currently
in clinical development are gapmers of this type. It
is also possible to use chemically modified oligonu-
cleotides that mimic the DNA structure and can recruit
RNase H, yet bind strongly to complementary RNA. 2′-
Fluoroarabinonucleic acid (2′F-ANA, Figure 2B) is the
best example of this type of oligonucleotide [33,34].
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Figure 2. Structures of some common chemically modified nucleotides. (A) Replacement of a non-bridging phosphate oxygen with sulphur
gives the phosphorothioate (PS) linkage, which dramatically increases nuclease stability. (B) Various sugar modifications are compatible
with unmodified DNA/RNA synthesis and increase binding affinity and nuclease stability. (C) PNA and PMO modifications have a neutral
backbone structure that is dramatically different from the sugar-phosphate backbone of natural oligonucleotides.
Blocking translation
ASOs that lack a contiguous stretch of DNA (or
DNA-like nucleotides) can also bind RNA and block
gene expression. These oligomers are known as ‘steric
blockers’ because they act by blocking the ribosome
rather than facilitating cleavage of RNA.
Besides the sugar-modified nucleotides discussed
above, steric blockers can be made from oligomers
that are quite different from DNA or RNA (Figure 2C).
Peptide nucleic acid (PNA) is an oligonucleotide mimic
whose bases are linked by amide bonds and whose
synthesis shares many features with peptide synthesis
[35]. Because the amide backbone is uncharged, bind-
ing is characterized by high rates of association and
high affinity [36,37]. Phosphorodiamidate morpholino
oligomers (commonly called PMOs or ‘morpholinos’)
are another uncharged DNA analogue [38]. PMOs do
not bind complementary targets with the high affinities
that characterize PNA binding, but have proven to be
effective agents inside cells. PMOs are widely used as
silencing agents in zebrafish [39,40].
Modulating splicing
mRNA is initially transcribed as a pre-mRNA con-
taining intervening sequences or introns. These introns
must be spliced out to form the mature mRNA. Up
to 95% of multi-exon genes are subject to alterna-
tive splicing in which the pre-mRNA is spliced differ-
ently to form multiple variants of the mature mRNA
[41]. Oligomers that target sequences within the pre-
mRNA can affect splicing and increase the production
of desired isoforms [42–48]. In this case, cleavage
of the target RNA is not desired; these strategies use
oligonucleotides that do not recruit RNase H, includ-
ing LNA or 2′-modified oligonucleotides or uncharged
analogues such as PNA or PMO oligomers.
An impressive variety of genes and conditions can
be treated by splice-switching oligonucleotides [42,43].
The most advanced target is the dystrophin gene, a
large (2.6 Mb) gene containing 97 exons that encodes
a protein essential for healthy muscle cells. Muta-
tions in the dystrophin gene cause muscular dystrophy.
In Duchenne muscular dystrophy (DMD), the most
severe form of muscular dystrophy, mutations cause
a frame shift resulting in no functional dystrophin
protein. However, oligonucleotides have been used to
remove the mutant exon and restore the proper reading
frame, producing a truncated but partially functional
dystrophin protein and potentially leading to milder
symptoms [46–48]. Researchers have also success-
fully modulated the splicing of several other thera-
peutic targets, including β-globin (for β-thalassaemia)
[44,49,50], SMN2 (for spinal muscular atrophy) [45],
HER2 or Bcl-x (for cancer) [51,52], and others [42,43].
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Targeting miRNAs
MicroRNAs (miRNAs) are endogenous small RNAs
that can regulate normal physiological processes and
affect disease [53–58]. miRNAs act through the RNAi
pathway and recognize target mRNAs through complex
patterns of recognition that are incompletely under-
stood. An increasing number of miRNAs have been
implicated in physiological processes that affect dis-
ease, and interfering with these miRNAs might increase
the expression of their target genes and provide thera-
peutic lead compounds.
ASOs that are complementary to miRNAs can
block their function [59–61]. For example, miR-122
is an abundant liver-specific miRNA implicated in
a variety of diseases including cancer and hepatitis
C [62]. Oligonucleotides complementary to miR-122
have been shown to alter liver metabolism [63,64]
and block hepatitis C virus replication [65,66]. Var-
ious chemistries have been shown to be active as
inhibitors of miRNA function, including PNA [67],
LNA [65–68], 2′-O-Me [69], 2′-MOE [64], and mor-
pholino [70].
siRNAs
Over the past decade, double-stranded short interfering
RNAs (siRNAs) have become widely used tools for
silencing gene expression. When a duplex RNA enters
cells, it binds the protein machinery of the RNA-
induced silencing complex (RISC) [71]. Synthetic
RNAs used for gene silencing are usually 19–22 bp
duplexes. This length is sufficient to form a stable
duplex and be recognized by RISC, but short enough to
avoid most of the strong interferon response provoked
by duplexes greater than 30 bp in length.
Since publication of the first report of gene silencing
in mammalian cells in 2001 [72], siRNAs have been the
subject of thousands of experimental studies aimed at
examining function. While antisense oligonucleotides
continue to be used for gene silencing, the robust nature
of siRNAs and the relative ease of identifying active
siRNAs have made them a favoured silencing tool for
many laboratories.
Chemical modifications and duplex RNAs
Unmodified duplex RNA is surprisingly stable and
chemical modification of siRNAs is usually not essen-
tial for silencing gene expression in cultured cells
(see Table 1). In vivo, however, unmodified siRNAs
are not highly active and chemical modification can
significantly improve their properties [73]. Chemically
modified siRNAs can feature improved nuclease stabil-
ity and an associated increase in the duration of action
[74–76]. Unmodified RNA is also rapidly cleared [77]
and chemical modification, complexation with carrier
Table 1. ASOs and siRNAs use different methods to overcome
similar obstacles. ASOs depend almost exclusively on chemical
modification to optimize their properties. On the other hand,
because siRNAs are always found as duplexes or associated with
proteins, chemical modification of siRNAs is not always required
for initial cell culture experiments
Principal methods for achieving the goal
Goal ASOs siRNA
Nuclease stability • Chemical
modification
• Duplex
structure
• Protein
association
• Chemical
modification
Binding affinity,
disruption of existing
target structure
• Chemical
modification
• Seed sequence
structural
preorganization
mediated by
Argonaute
Overcoming immune
stimulation
• Chemical
modification
• Chemical
modification
Specificity of
knockdown
• Careful sequence
selection
• Careful sequence
selection
• Chemical
modification
Cellular uptake • Chemical • Conjugation
modification • Formulation
• Conjugation
• Formulation
agent, and local delivery to a disease target can help to
achieve improved in vivo results.
Several patterns of chemical modification show
increased potency across several sequences [76,78,79].
The introduction of double-stranded RNA into cells
can activate the innate immune system [80–82]; this
immune activation may be able to be harnessed for
therapeutic benefit [83–87] but can also lead to dose-
limiting toxicity when siRNAs are delivered system-
ically [88]. Chemical modifications can be used to
reduce the immunogenicity of siRNAs [79,88,89].
Chemical modification becomes particularly important
as an siRNA progresses towards clinical use [90,91].
The architecture of an siRNA duplex can also be
modified. For example, longer RNA duplexes are rec-
ognized by Dicer, a component of the RISC machinery,
and may have higher potency than their 21-mer coun-
terparts [92,93].
Identifying a useful ASO or siRNA for gene
silencing
The first step in any project is to identify a biol-
ogy problem or disease state where manipulation of
gene expression might produce a useful phenotype or
physiological effect. The second step is to identify one
or more target genes to manipulate. Efficient agents
may already have been identified in the literature. If
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no such data exist, commercial suppliers may offer
duplex RNAs that have been validated for inhibition of
the target gene. If commercial RNAs are unavailable,
are too expensive, or are inadequate, investigators can
experimentally identify ASOs or siRNAs themselves.
There are algorithms for siRNA design [94–96],
but none is perfect and it will probably be necessary
to test several duplex RNAs to find sequences that
are sufficiently active and selective. Various groups
have proposed computational [97–99] or experimen-
tal [99–104] methods for identifying potent ASOs.
Aspects of mRNA secondary structure can be roughly
predicted, but algorithms such as the popular mFOLD
do not take into account factors such as tertiary struc-
ture or the involvement of RNA binding proteins, and
so they are of limited utility in practice [105]. Ulti-
mately, if a group is serious about finding a potent
ASO, they should test as many oligonucleotides as time
and budget permit [106,107].
Control experiments: you can never have too
many
Regardless of whether ASOs or siRNAs are used for
gene silencing, it is essential to use proper controls
[108]. Understanding off-target effects can help inves-
tigators choose controls appropriately. ASOs and siR-
NAs are large synthetic molecules and can act in
ways independent of Watson–Crick base pairing. For
ASOs, this includes non-specific binding to proteins
both in serum and inside cells. Phosphorothioate back-
bone oligonucleotides are particularly liable to bind
proteins—this is the source of their slower clearance
from serum, but also the source of much of their tox-
icity [109]. Oligonucleotides can fold into complex
secondary structures and bind proteins in a sequence-
specific manner related to shape rather than pairing
[110].
For siRNAs, cells can recognize double-stranded
RNA and activate the innate immune system [80–82]
and this immunostimulatory activity has been misinter-
preted as RNA interference effects [111,112]. Finally,
high concentrations of siRNA can saturate the RNAi
machinery, leading to a global perturbation of miRNA-
mediated regulation [113–115].
An ASO or siRNA will always have partial comple-
mentarity to non-target transcripts, and this can cause
unintended gene repression and misleading phenotypes
[116,117]. For siRNAs, one of the most common off-
target effects occurs through 7–8 nucleotide comple-
mentarity at the 5′-end of the guide strand (the so-called
‘seed region’) to sites in the 3′-untranslated region of
other genes. This type of base pairing is a prerequi-
site for miRNA-mediated gene repression, and partially
complementary siRNA duplexes can enter the miRNA
pathway and repress non-target transcripts [117,118].
Careful use of chemistry and duplex design can help
to alleviate this type of off-target effect. For example,
A B
Figure 3. Typical mismatched and scrambled controls. (A) A duplex
with several pairs of bases exchanged (from one strand to the other)
should maintain very similar properties to the parent duplex but
lose affinity for its target mRNA. (B) A scrambled control can
be made by moving blocks of bases with respect to the parent
oligomer.
including two 2′-O-Me-RNA nucleotides at the 5′-end
of the siRNA reduces its ability to enter the miRNA
pathway [117,119]. siRNA designs that ensure loading
of the correct guide strand into RISC can also help to
reduce off-target effects [120–126].
It is impossible to avoid some level of off-
target effects in oligonucleotide-mediated gene silenc-
ing—the goal is to minimize them by careful use of
chemistry and to use multiple approaches with non-
overlapping off-target effects so that an observed phe-
notype can be confidently ascribed to recognition of
the desired target. For example, an investigator may
be testing the hypothesis that inhibition of a protein
will lead to decreased cell proliferation. How can one
build a case that the observed protein knockdown and
decreased cell proliferation are not indirect effects?
Several types of controls are recommended for any
oligonucleotide experiment:
• When multiple ASOs or siRNAs target the same
gene, they should have the same on-target effect
but different off-target effects. Thus, possession
of multiple ASOs or siRNAs that are complemen-
tary to the target mRNA and produce the same
phenotype provides one piece of evidence sup-
porting a relationship between recognition of the
target mRNA, gene silencing, and phenotype.
• Experiments should include negative control
compounds containing mismatched bases relative
to the target mRNA or having blocks of bases
moved relative to the sequence of the parent
oligomer (Figure 3). Sequences that are closely
related to the oligonucleotide of interest are more
likely to have similar immunogenic or other off-
target effects, making them better controls than
totally unrelated sequences. An ideal mismatched
or scrambled control does not significantly per-
turb the levels of a gene of interest.
• Protein and RNA levels of the target gene should
both be tested where possible. If using siRNA
or an RNase H competent ASO, both protein
and RNA should decrease. A different result
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should raise suspicion about the mechanism of
the silencing observed.
• The dose–response of any knockdown should be
tested and experiments should be carried out at
the lowest possible concentration.
• For gapmers or siRNAs, a technique called rapid
amplification of 5′-cDNA ends (5′-RACE) can be
used to verify that the targeted transcript is being
cleaved at the predicted site [127–130]. While
valuable, it is important to note that 5′-RACE
merely detects cleavage; it is not quantitative and
is not an indication of efficiency.
• Finally, when possible, the ultimate control for
gene silencing experiments is a functional rescue
by an exogenous copy of the gene of interest con-
taining silent mutations at the oligonucleotide’s
target site. Nevertheless, these experiments can
be quite challenging, depending on the biological
system being studied.
Off-target effects are a significant concern for lab-
oratory use and clinical development of nucleic acid
acids. Unintended phenotypes are, however, a concern
for the development of any other type of drug including
small molecules and proteins. The solution for mini-
mizing off-target effects for nucleic acids is the same as
for other classes of drug—iterative testing and rational
optimization.
Introducing ASOs or siRNAs into cultured cells
The most common method for promoting uptake of
ASOs and siRNAs in cell culture involves the use
of cationic lipids to transfect nucleic acids. Mixing
cationic lipid with negatively charged nucleic acids
yields a complex that can cross cell membranes and
release active oligonucleotide into the cytoplasm of
cells.
Many different cationic lipids are available and
activity depends on the cell line used. Even for a
given cell line, the preferred lipid may vary depending
on whether an ASO or siRNA is being transfected.
Not all cell lines can be transfected using cationic
lipid, and if literature precedent is unavailable, it may
be necessary to experimentally test different cationic
lipids to find one that can successfully transfect a
cell line of interest. It is also possible to electroporate
oligonucleotides into cells [131–133]. This method can
be highly effective and useful for cell lines that cannot
be readily transfected by lipid, but requires specialized
equipment and expertise.
Recently, it has become apparent that active ASOs
can freely enter some cell lines without the need to
add lipid [134,135]. The transfection protocol is thus
simplified and any off-target effects due to exposure
of cells to lipid are avoided. The method can also be
used with cell lines that are not compatible with lipid-
mediated transfection. However, higher concentrations
of ASO are needed relative to the amounts used in
lipid-mediated transfections.
Delivery of ASOs and siRNAs in vivo
As gene silencing technologies move from cultured
cells into animal models and ultimately clinical appli-
cation, the challenge of delivery increases. Delivering
oligonucleotides in whole organisms requires cross-
ing many barriers [136,137]. Degradation by serum
nucleases, clearance by the kidney, or inappropriate
biodistribution can prevent the oligonucleotide from
ever reaching its target organ. The oligonucleotide must
pass through the blood vessel wall and navigate the
interstitial space and extracellular matrix. Finally, if
the oligonucleotide succeeds in reaching the appropri-
ate cell membrane, it will usually be taken up into an
endosome, from which it must escape to be active.
ASOs are usually delivered in saline and rely
on chemical modifications to enable uptake. Their
phosphorothioate backbone binds to serum proteins,
slowing excretion by the kidney [109]. The aro-
matic nucleobases also interact with other hydrophobic
molecules in serum and on cell surfaces. Many types
of cells in vivo express surface receptors that actively
take up oligonucleotides; these are often lost when cells
are cultured, which explains why lipid seems more
important for delivering ASOs in culture than in vivo
[138].
Delivery is even more challenging for duplex RNAs
than single-stranded oligonucleotides. In an siRNA, all
of the aromatic nucleobases are on the inside, leav-
ing only heavily hydrated phosphates on the outside
of the duplex. This hydrated surface interacts poorly
with cell surfaces and is rapidly excreted in the urine.
Thus, researchers have invested heavily in the develop-
ment of delivery vehicles for siRNAs [137,139–142].
The predominant technologies for delivering siRNAs
involve complexing the RNA with cationic and neu-
tral lipids [139,143,144], although encouraging results
have also been obtained using peptide transduction
domains [145] and cationic polymers [130]. Including
PEGylated lipids in the formulation prolongs the cir-
culating half-life of the particles [146]. Conjugation of
cholesterol to one strand of the siRNA gave effective
knockdown in the liver of mice [147], but the quantities
of material required (50 mg/kg) were several orders of
magnitude higher than current lipid-based formulations
(as low as 0.01 mg/kg [148]).
Lipid-based formulations are ideal for targeting the
liver, since lipid nanoparticles are readily taken up
by liver cells. For targeting other organs follow-
ing systemic administration, researchers have conju-
gated various ligands to the siRNA itself or included
them as part of a formulation. Promising strategies
include the use of aptamers [149], antibodies/fragments
[150], vitamins [151], and other targeting ligands
[130,152].
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siRNA or ASO?
For cell culture experiments, siRNAs will often be the
better choice. It is relatively simpler to discover potent
siRNAs and it may be easier to obtain siRNAs since
unmodified RNA works with high potency. ASOs, on
the other hand, must contain chemical modifications
to be active inside cells. For experiments where the
goal is to develop compounds for testing in animals
or investigate therapeutic development, the choice is
more complex.
Several studies have directly compared the activity
of various ASOs and siRNAs [105,153–157]. These
studies can be misleading if one of the compounds
contains suboptimal chemistry or sequence selection
(eg first-generation PS-DNA ASOs); both potent and
effective antisense oligonucleotides or siRNAs can
generally be found if researchers are willing to invest
in optimizing each technology [158]. An ideal target
sequence for an ASO is not necessarily ideal for an
siRNA, and vice versa.
In vivo, the choice of ASO versus siRNA is unset-
tled and will continue to evolve over the next decade.
The challenges involved in delivering oligonucleotides
to a given target tissue should be considered before
choosing between them. For example, in animal mod-
els of Huntington’s disease, antisense oligonucleotides
or siRNAs have been infused directly into the cen-
tral nervous system. In the case of single-stranded
oligonucleotides, researchers observed wide distribu-
tion throughout the mouse CNS including deep-brain
penetration [159]. In contrast, others found that siRNA
infused into the monkey brain penetrated into brain tis-
sue only up to about 12 mm from the site of infusion
[159].
ASOs and siRNAs share important similarities as
drug candidates. Both platforms are intended to mod-
ulate gene expression. Both are nucleic acids and con-
tain an antisense strand intended to recognize a target
mRNA. They also have important differences. ASOs
have one strand, while siRNAs have two, a basic fact
that may lower cost and simplify delivery. On the other
hand, siRNAs have proven to be a more robust tech-
nology in cell culture in the hands of most users. It is
not clear whether this will be true in vivo, but the pos-
sibility that siRNAs might have superior potency for
at least some applications is a major driving force for
their continued development.
Clinical progress
The clinical progress of oligonucleotide drugs has been
slow because realizing the potential for ASOs and
duplex RNAs requires inventing a new model for
pharmaceutical development that allows large, highly
charged molecules to be synthesized economically,
distribute to target tissues, enter cells, and function
within acceptable limits for toxicity. Oligonucleotides
are unlike traditional small molecule drugs (<500–700
molecular weight) and much effort has been required
to understand their properties and optimize them.
Antibody therapeutics provide a useful comparison.
This class of molecules is now a major source of new
drugs, but they also required many years to develop.
Oligonucleotides may eventually have similar success.
One ASO has been approved by the FDA and at least
22 oligonucleotide drugs are in phase II or III clinical
trials (Table 2). Many more are earlier in the process
of clinical development [91,158,160,161].
ASO-mediated gene inhibition in the clinic
ASOs began clinical development in the 1990s with
first-generation compounds consisting of phosphoroth-
ioate DNA. One programme from ISIS Pharmaceuti-
cals succeeded, leading to FDA approval of fomivirsen
for treatment of CMV retinitis [162,163]. Development
was facilitated by the location of the disease target and
mode of administration. Fomivirsen is administered
directly into the eye, reducing the amount of material
needed and decreasing concerns about systemic side
effects. One lesson for future work from these studies
was that local delivery of oligonucleotides can sim-
plify clinical studies and contribute to efficient trial
design.
Other trials, however, were not successful. Drugs
from Genta, Hybridon, and ISIS Pharmaceuticals failed
in phase III clinical trials. Reasons that contribute
to the lack of success include (i) incomplete under-
standing of the biological target and the consequences
of its repression; (ii) the use of relatively inefficient
first-generation chemically-modified PS-DNA oligonu-
cleotides; and (iii) targeting disease tissues that are
not prime locations for oligonucleotide biodistribution.
More recent trials have begun to revive optimism.
Gapmer designs with optimized chemistry have led
to improved potencies [28,164]. Biodistribution of
oligonucleotides is better understood and some of the
more promising trials involve inhibiting the expression
of genes in the liver, an organ known to accumulate
ASO [165]. The importance of convenient markers of
activity has been recognized. Such markers allow an
ASO-mediated down-regulation of target gene expres-
sion to be demonstrated early in clinical trials, permit-
ting resources to be devoted to the most promising drug
candidates.
An example of the new wave of more promising
ASOs is mipomersen, an ASO from ISIS Pharma-
ceuticals designed to inhibit the expression of ApoB
(Figure 4) [166]. Mipomersen is a gapmer contain-
ing phosphorothioate-modified DNA and 2′-O-MOE-
RNA. Data from animal models show a robust and
prolonged repression of ApoB expression [167]. In
patients, the desired physiological response upon sys-
temic administration was demonstrated by monitor-
ing serum LDL-cholesterol: all primary, secondary,
Copyright  2011 Pathological Society of Great Britain and Ireland. J Pathol 2012; 226: 365–379
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
372 JK Watts and DR Corey
Ta
bl
e
2.
Se
le
ct
ed
ol
ig
on
uc
le
ot
id
e
dr
ug
ca
nd
id
at
es
in
ad
va
nc
ed
cl
in
ic
al
tr
ia
ls
(p
ha
se
II
or
hi
gh
er
).
Be
si
de
s
re
fe
re
nc
es
lis
te
d
in
th
e
ta
bl
e,
in
fo
rm
at
io
n
w
as
ta
ke
n
fr
om
co
m
pa
ny
w
eb
si
te
s
an
d
re
fs
15
8
an
d
16
0
Dr
ug
Co
m
pa
ny
Ph
as
e
Ta
rg
et
ge
ne
an
d
di
se
as
e
N
ot
es
an
d
re
fe
re
nc
es
m
RN
A-
ta
rg
et
ed
an
tis
en
se
ol
ig
on
uc
le
ot
id
e
dr
ug
ca
nd
id
at
es
M
ip
om
er
se
n
IS
IS
/G
en
zy
m
e
III
Ap
oB
fo
rh
yp
er
ch
ol
es
te
ro
la
em
ia
PS
-M
O
E
ga
pm
er
,i
nt
ra
ve
no
us
de
liv
er
y;
m
et
al
le
nd
po
in
ts
in
fo
ur
ph
as
e
III
tr
ia
ls
[1
66
]
O
G
X-
01
1
(C
us
tir
se
n)
IS
IS
/T
ev
a/
O
nc
oG
en
ex
III
Cl
us
te
rin
fo
rp
ro
st
at
e,
N
SC
LC
an
d
br
ea
st
ca
nc
er
PS
-M
O
E
ga
pm
er
[1
84
]
AP
12
00
9
(T
ra
be
de
rs
en
)
An
tis
en
se
Ph
ar
m
a
III
TG
F-
β
2
fo
rb
ra
in
ca
nc
er
PS
-D
N
A
G
S-
10
1
(A
ga
ni
rs
en
)
G
en
e
Si
gn
al
III
In
su
lin
re
ce
pt
or
su
bs
tr
at
e-
1
fo
rc
or
ne
al
ne
ov
as
cu
la
riz
at
io
n
PS
-D
N
A,
to
pi
ca
ld
el
iv
er
y
(e
ye
dr
op
s)
LO
R-
20
40
Lo
ru
s
II
Ri
bo
nu
cl
eo
tid
e
re
du
ct
as
e
fo
rc
an
ce
r
PS
-D
N
A
AS
M
8
Ph
ar
m
ax
is
II
M
ul
tip
le
ta
rg
et
s
fo
ra
lle
rg
ic
as
th
m
a
Tw
o
PS
-D
N
A
AS
O
s,
de
liv
er
ed
by
in
ha
la
tio
n
Ar
ch
ex
in
Re
xa
hn
II
AK
T-
1
fo
rc
an
ce
r
PS
-D
N
A
LY
21
81
30
8
IS
IS
/L
ill
y
II
Su
rv
iv
in
fo
rc
an
ce
r
PS
-M
O
E
ga
pm
er
IS
IS
-E
IF
4E
Rx
IS
IS
/L
ill
y
II
eI
F4
E
fo
rc
an
ce
r
PS
-M
O
E
ga
pm
er
O
G
X-
42
7
IS
IS
/O
nc
oG
en
ex
II
H
sp
27
fo
rc
an
ce
r
PS
-M
O
E
ga
pm
er
Al
ic
af
or
se
n
IS
IS
/A
tla
nt
ic
II
IC
AM
-1
fo
ru
lc
er
at
iv
e
co
lit
is
Av
ai
la
bl
e
w
he
n
re
qu
es
te
d
by
ph
ys
ic
ia
ns
fo
rp
at
ie
nt
s
w
ith
in
fla
m
m
at
or
y
bo
w
el
di
se
as
e
AE
G
35
15
6
Ae
ge
ra
II
XI
AP
fo
rc
an
ce
r
PS
2′
-O
-M
e
ga
pm
er
Sp
lic
e-
sw
itc
hi
ng
ol
ig
on
uc
le
ot
id
e
dr
ug
ca
nd
id
at
es
PR
O
05
1
(G
SK
24
02
96
8)
Pr
os
en
sa
/G
SK
III
Dy
st
ro
ph
in
(e
xo
n
51
sk
ip
pi
ng
)f
or
DM
D
20
-m
er
PS
,f
ul
ly
-2
′ -
O
-M
e
AS
O
[4
6]
AV
I-
46
58
AV
IB
io
Ph
ar
m
a
II
Dy
st
ro
ph
in
(e
xo
n
51
sk
ip
pi
ng
)f
or
DM
D
30
-m
er
m
or
ph
ol
in
o
[4
8]
PR
O
04
4
Pr
os
en
sa
I/I
I
Dy
st
ro
ph
in
(e
xo
n
44
sk
ip
pi
ng
)f
or
DM
D
PS
,f
ul
ly
-2
′ -
O
-M
e
AS
O
An
ti-
m
iR
ol
ig
on
uc
le
ot
id
e
dr
ug
ca
nd
id
at
e
M
ira
vi
rs
en
(S
PC
36
49
)
Sa
nt
ar
is
II
m
iR
-1
22
fo
rh
ep
at
iti
s
C
vi
ru
s
LN
A-
m
od
ifi
ed
15
-m
er
an
ti-
m
iR
ol
ig
on
uc
le
ot
id
e,
de
liv
er
ed
in
tr
av
en
ou
sl
y
[6
6]
si
RN
A
dr
ug
ca
nd
id
at
es
AL
N
-R
SV
01
Al
ny
la
m
/C
ub
is
t/
Ky
ow
a
Ki
rin
II
RS
V
(v
ira
ln
uc
le
oc
ap
si
d)
U
nm
od
ifi
ed
si
RN
A,
in
tr
an
as
al
or
in
ha
le
d
PF
-6
55
Q
ua
rk
/P
fiz
er
/S
ile
nc
e
II
RT
P8
01
fo
rw
et
AM
D
an
d
di
ab
et
ic
m
ac
ul
ar
oe
de
m
a
Ch
em
ic
al
ly
m
od
ifi
ed
,i
nt
ra
oc
ul
ar
Q
PI
-1
00
2
Q
ua
rk
/N
ov
ar
tis
/S
ile
nc
e
II
p5
3
fo
ra
cu
te
re
na
lf
ai
lu
re
Ch
em
ic
al
ly
m
od
ifi
ed
,i
nt
ra
ve
no
us
Ex
ce
lla
ir
Za
Be
Co
r
II
SY
K
ki
na
se
fo
ra
th
sm
a
In
ha
le
d
O
th
er
ad
va
nc
ed
ol
ig
on
uc
le
ot
id
e
dr
ug
ca
nd
id
at
es
IM
O
-2
05
5
Id
er
a/
M
er
ck
II
TL
R-
9
ac
tiv
at
io
n
fo
rc
an
ce
rt
re
at
m
en
t
Cp
G
-r
ic
h
ol
ig
on
uc
le
ot
id
e
ca
us
es
ac
tiv
at
io
n
of
TL
R-
9
[1
85
]
G
RN
16
3L
(Im
et
el
st
at
)
G
er
on
II
Te
lo
m
er
as
e
in
hi
bi
to
rf
or
ca
nc
er
tr
ea
tm
en
t
13
-m
er
N
3′
th
io
ph
os
ph
or
am
id
at
e
ol
ig
on
uc
le
ot
id
e
(li
pi
d
co
nj
ug
at
e)
;i
nh
ib
its
te
lo
m
er
as
e
by
di
re
ct
bi
nd
in
g,
no
t
an
an
tis
en
se
ef
fe
ct
[1
86
,1
87
]
Copyright  2011 Pathological Society of Great Britain and Ireland. J Pathol 2012; 226: 365–379
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
Gene silencing by synthetic nucleic acids 373
Figure 4. Mechanism of action of mipomersen.
and tertiary endpoints have been met in four separate
phase III clinical trials [166]. Some toxic effects have
been noted, and while these have been relatively
mild, they may (at least initially) limit the patient
population to patients who are at the most severe risk
for atherosclerosis [168].
Eleven other traditional antisense oligonucleotides
are in advanced clinical trials (Table 2). Targets rele-
vant to cancer are the most highly represented, but there
are also ASOs in trials against asthma, corneal neovas-
cularisation, and ulcerative colitis. Many of these ASOs
contain optimized chemistry and are taking advantage
of the lessons learned over the past two decades in
terms of delivery.
Modulating splicing in the clinic
Three splice-switching ASOs are in phase II or III
clinical trials, all of them for treatment of Duchenne
muscular dystrophy (DMD) (Figure 5). Prosensa has
developed 2′-O-Me phosphorothioate oligonucleotides
[46], while AVI BioPharma has favoured the devel-
opment of morpholino oligomers [48]. Both drugs
show promise in clinical development, but two partic-
ular challenges face splice-switching oligomers against
DMD—the first is that of delivery. For significant clin-
ical benefit, the ASOs would need to enter muscle
tissue [144], including heart tissue. Currently, all of
the splice-switching ASOs are delivered naked and are
not efficiently taken up into heart muscle cells (car-
diomyocytes) in particular. Delivery is aided to some
degree by the weakened, ‘leaky’ nature of dystrophic
muscle cells, but as the drug begins to take effect and
the muscle cells recover, they are not such easy targets
for further drug uptake. One possible solution is to use
a targeted delivery system such as a cell-penetrating
peptide [169,170]. Peptide-conjugated PMOs (PPMOs)
take advantage of an active cell-internalization process
and are taken up far more efficiently than unconju-
gated PMOs [171–177]. Even at lower doses, they
distribute to more muscle cells body-wide, including
healthy muscle cells and cardiomyocytes.
The second challenge is that DMD is caused by a
large family of mutations. Exon 51 skipping would
in principle be helpful for ∼13% of DMD patients,
including those with deletions of exons 50, 52, 45–50,
48–50 or 49–50. Exon 44 skipping could help another
∼6% of DMD patients. Further splice-switching ASOs
could be developed that would help other patients,
but the populations become increasingly small. It
is unclear whether the regulatory process could one
day be adjusted to approve, for example, personal-
ized dystrophin-targeted splice-switching ASOs as a
class [170]. Extensive clinical trials for a sequence
with a small target population might be prohibitively
expensive.
Clinical trials for ASOs targeting microRNA
The first anti-miR oligonucleotide to be tested in
humans is being developed by Santaris Pharmaceuti-
cals. Miravirsen is a 15-mer phosphorothioate oligonu-
cleotide containing eight LNA modifications. It is
complementary to miR-122 and designed to inhibit
replication of hepatitis C virus (HCV) [65,66]
(Figure 6). Since miravirsen was the first anti-miR to
be tested in humans, no one could predict the effect of
inhibiting a miRNA, thus simultaneously de-repressing
a family of mRNA targets in humans. Accordingly,
phase I testing started conservatively at 0.2 mg/kg
delivered intravenously or subcutaneously. However,
the drug was so well tolerated at the planned end-
point dose of 6 mg/kg that the trial was extended to
a 12 mg/kg upper dose.
While miravirsen is designed to treat HCV, inhi-
bition of miR-122 also lowers plasma cholesterol
(Figure 6). Researchers at Santaris made use of this
fact to demonstrate dose-dependent pharmacology in
their phase I trial in spite of the fact that the trial
enrolled healthy volunteers. Phase II clinical trials on
HCV patients began in September 2010.
siRNAs in the clinic
A decade after the first siRNA experiments [72,178],
a dozen siRNA drugs are in clinical development [91].
The four most advanced are in phase II trials (Table 2).
As with ASOs, some of the earliest drugs to enter trials
were very simple ‘first-generation’ siRNAs containing
no chemical modifications. Two of these drugs, both
targeting the VEGF pathway in the eye, had reached
advanced clinical trials (phase II and phase III) but
were withdrawn [91]. The therapeutic siRNA field is
still young; however, many valuable lessons have been
learned from 20 years of clinical work with ASOs that
can now be applied to siRNA clinical development
[179].
While cationic lipid-based formulations are clearly
dominant in terms of potency, they deliver siRNAs into
the endosome, the part of the cell where innate immune
receptors are most intensely displayed. This means that
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A
B
Figure 5. Mode of action of drug candidates PRO051 and AVI-4568. (A) This DMD patient is missing dystrophin exon 50. Splicing of
the pre-mRNA gives mature mRNA that is out-of-frame and so no functional dystrophin can be produced. (B) In the presence of a
splice-switching ASO that favours exclusion of exon 51, the cell splices exon 49 to exon 52, which restores the reading frame and causes
translation of a shorter but partially functional dystrophin protein.
Figure 6. miR-122 is a liver-specificmiRNA that regulates multiple
pathways. Therapeutic inhibition of miR-122 by miravirsen blocks
HCV replication and lowers plasma cholesterol.
siRNAs delivered by cationic lipid-based formulations
are particularly vulnerable to immune stimulation. As
such, a phase I drug candidate targeting ApoB from
Tekmira Pharmaceuticals (http://www.tekmirapharm.
com) was withdrawn from clinical trials after one
patient at the highest dose level showed severe flu-
like symptoms typical of an immune response. Tek-
mira halted the trial in autumn 2009 and opti-
mized both the lipid delivery agent and the siRNA
cargo, decreasing the immunogenicity of both, before
returning to clinical testing of the improved candi-
date.
Conclusions and future prospects
The field of oligonucleotide therapeutics has often
swung from irrational optimism to irrational despair.
In the laboratory as well, gene knockdown experiments
have fallen in and out of favour with researchers. In
reality, oligonucleotides are useful tools with strengths
and weaknesses. Different oligonucleotide technolo-
gies have different strengths, and many of the pen-
dulum swings in the field have caused a switch from
one oligonucleotide technology to another [180–183].
If researchers approach the oligonucleotide toolbox
with careful experimentation and the broadest possi-
ble understanding, we believe that they will continue
to find useful tools for both laboratory experiments and
therapeutic development.
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